Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BDTX

BDTX - Black Diamond Therapeutics Inc Stock Price, Fair Value and News

$2.590.00 (0.00%)
Market Closed

35/100

BDTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

35/100

BDTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.09

Target 3M

$2.44

Target 6M

$2.29

BDTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BDTX Price Action

Last 7 days

0.8%

Last 30 days

4.0%

Last 90 days

-32.2%

Trailing 12 Months

4.9%

BDTX RSI Chart

BDTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BDTX Valuation

Market Cap

147.6M

Price/Earnings (Trailing)

6.86

Price/Sales (Trailing)

130.1

Price/Free Cashflow

6.91

BDTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.09

Target 3M

$2.44

Target 6M

$2.29

BDTX Fundamentals

BDTX Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

BDTX Earnings

Earnings (TTM)

21.5M

Earnings Growth (Yr)

45.38%

Earnings Growth (Qtr)

19.53%

BDTX Profitability

Return on Equity

17.04%

Return on Assets

13.63%

Free Cashflow Yield

14.47%

BDTX Investor Care

Shares Dilution (1Y)

0.69%

Diluted EPS (TTM)

0.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
202401.8M1.7M0
20232.3M2.4M2.3M1.9M
20222.7M02.3M2.2M
20214.4M4.5M4.1M3.5M
20201.2M2.1M3.2M4.0M
2019000461.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Black Diamond Therapeutics Inc

BDTX
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEblackdiamondtherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES65

Black Diamond Therapeutics Inc Frequently Asked Questions

BDTX is the stock ticker symbol of Black Diamond Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Black Diamond Therapeutics Inc is 147.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BDTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether BDTX is over valued or under valued. Whether Black Diamond Therapeutics Inc is cheap or expensive depends on the assumptions which impact Black Diamond Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BDTX.

As of Wed Jan 28 2026, BDTX's PE ratio (Price to Earnings) is 6.86 and Price to Sales (PS) ratio is 130.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BDTX PE ratio will change depending on the future growth rate expectations of investors.